Researchers assessed transcatheter arterial chemoembolization, using autologous blood clot as an embolizing agent (short-TAE (S-TAE)), for the treatment of unresectable hepatocellular carcinoma less than 2 cm.
The team’s findings are published in the April issue of the Journal of Clinical Gastroenterology.
The research team treated 28 consecutive patients with unresectable hepatocellular carcinoma less than 2 cm in diameter using S-TAE alone.
All patients had documented cirrhosis; 20 with Child class B and 8 with class C.
The team performed S-TAE by injecting a mixture of iodized oil and anticancer drugs, followed by embolization of hepatic arteries with autologous blood clot.
A total of 147 sessions of embolization with clots were performed.
| Child staging of cirrhosis is the sole factor significantly predicting survival.|
|Journal of Clinical Gastroenterology|
S-TAE maintained patency of hepatic arteries.
The researchers estimated overall survival rates at 1, 3, 5, and 8 years to be 89%, 52%, 34%, and 17%, respectively. These rates are higher than previously documented rates for the gelfoam method.
Survival for Child class B patients was significantly better than that for Child class C patients (p < 0.05).
In addition, Cox’s proportional hazard model demonstrated that Child staging of cirrhosis was the sole factor significantly predicting patient’s survival (p < 0.05).
Dr Toshiaki Gunji’s team concluded, “The long-term outcomes of S-TAE for unresectable hepatocellular carcinoma less than 2 cm are satisfactory”.
“Prognosis of these patients was significantly dependent on clinical stages of coexisting liver cirrhosis.”